Healthcare / Medical DevicesStockholm
$48.15
-1.75 (-3.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $351.0M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.0B
P/E
17.1x
↓EV/EBITDA
8.7x
↓ROE
14.0%
↑Gross Margin
18.3%
↓Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.2%
FCF CAGR
—
FCF margin
2.9%
FCF / Net income
0.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.46B · net income $777.0M · FCF $273.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.46B | $9.46B | $9.66B | $9.55B | $10.77B |
| Net Income | $777.0M | $777.0M | $658.0M | $435.0M | $697.0M |
| EBITDA | $1.60B | $1.60B | $1.51B | $1.27B | $1.48B |
| EPS | 2.88 | 2.88 | 2.44 | 1.61 | 2.59 |
| Gross Margin | 18.3% | 18.3% | 16.7% | 14.0% | 13.3% |
| Operating Margin | 10.4% | 10.4% | 9.3% | 6.9% | 7.8% |
| Net Margin | 8.2% | 8.2% | 6.8% | 4.6% | 6.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.27 | 0.36 | 0.36 |
| Current Ratio | 1.68 | 1.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $273.0M | $273.0M | $737.0M | $351.0M | $-49.0M |
| Returns | |||||
| ROE | 14.0% | 14.0% | 11.5% | 8.4% | 12.9% |
| Valuation | |||||
| P/E | 17.14 | 17.14 | 22.34 | 30.40 | 21.53 |
| EV/EBITDA | 8.74 | 8.74 | 10.28 | 11.32 | 10.81 |
| P/B | 2.34 | 2.34 | 2.56 | 2.55 | 2.79 |
| Growth & Yield | |||||
| Revenue Growth | -2.1% | -2.1% | 1.2% | -11.4% | — |
| EPS Growth | 18.0% | 18.0% | 51.6% | -37.8% | — |
| Dividend Yield | 3.4% | 3.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
14.1%
EPS terminal req.
$4.27
Spread vs growth
4.0%
5Y implied EPS CAGR
12.4%
EPS terminal req.
$5.17
Spread vs growth
5.6%
10Y implied EPS CAGR
11.2%
EPS terminal req.
$8.33
Spread vs growth
6.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.9%
Start / end P/E
24.2x → 16.7x
EPS bridge
2.44 → 2.88
Residual
-5.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.